During a live event, Omid Hamid, MD, discussed the logistics and multidisciplinary process of using tumor-infiltrating ...

More than 35 years after it was invented, a therapy that uses immune cells extracted from a person’s own tumour is finally hitting the clinic. At least 20 people with advanced melanoma have embarked ...

Tumor-infiltrating lymphocytes (TILs) are a grouping of mostly T cells that enter tumors and elicit an initial immune response. But as Jason Bock, PhD, co-founder and CEO of CTMC, explains, “These ...

CT scans from a lung cancer patient treated at MSK, taken from two different views. These images show the patient’s chest before TIL therapy and again six weeks after treatment. The pretreatment ...

Please provide your email address to receive an email when new articles are posted on . Clinicians should have a low threshold for stopping interleukin-2 when treating with tumor-infiltrating ...

TIL therapy uses a patient's immune cells to target cancer, offering a novel treatment for advanced melanoma after anti-PD-1/PD-L1 therapy failure. The FDA approved Amtagvi (lifileucel) in 2024 for ...

Iovance's tumor infiltrating lymphocyte cell therapy candidate, lifileucel, has shown promising results in a study of melanoma patients, with a 31.4% overall response rate. Lifileucel uses a novel ...

Cervical cancer remains a global health burden, with over 570,000 new cases and 311,000 deaths annually. Existing treatment options for advanced stages, such as chemotherapy and checkpoint inhibitors, ...

Engineering a patient’s immune cells into cancer treatments works for treating blood cancers, but has fallen short in solid tumors—until now. An Iovance Biotherapeutics treatment employing a different ...

Iovance's Q2 2024 revenue of $31.1 million surpassed analyst expectations. Amtagvi, Iovance's TIL therapy, generated $12.8 million in its first full quarter post-approval. Iovance's ongoing trials in ...